OCERA THERAPEUTICS, INC. (NASDAQ:OCRX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
2017 Annual Meeting of Stockholders (the Annual Meeting). A total
of 19,845,322 shares of the Companys common stock were present or
represented by proxy at the Annual Meeting. At the Annual
Meeting, the stockholders voted on the following three proposals
and cast their votes as described below.
Annual Meeting to serve until the annual meeting of stockholders
in 2018 and until their respective successors are duly elected
and qualified or until their earlier resignation or removal.
|
FOR
|
WITHHELD
|
BROKER NON- VOTES
|
||||
|
Eckard Weber, M.D.
|
8,727,395
|
91,449
|
11,026,478
|
|||
|
Linda S. Grais, M.D.
|
8,721,704
|
97,140
|
11,026,478
|
|||
|
Steven P. James
|
8,731,966
|
86,878
|
11,026,478
|
|||
|
Nina Kjellson
|
8,731,706
|
87,138
|
11,026,478
|
|||
|
Willard Dere, M.D.
|
8,731,786
|
87,058
|
11,026,478
|
|||
|
Anne VanLent
|
8,737,051
|
81,793
|
11,026,478
|
|||
|
Wendell Wierenga, Ph.D.
|
8,731,369
|
87,475
|
11,026,478
|
advisory resolution on the executive compensation of the Companys
named executive officers.
|
FOR
|
AGAINST
|
ABSTAIN
|
BROKER NON- VOTES
|
|||
|
8,534,322
|
248,076
|
36,446
|
11,026,478
|
Ernst Young LLP as the Companys independent registered public
accounting firm for the year ending December 31, 2017.
|
FOR
|
AGAINST
|
ABSTAIN
|
||
|
19,702,615
|
104,976
|
37,731
|
About OCERA THERAPEUTICS, INC. (NASDAQ:OCRX)
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
